CRISPR shows promise for treating hair loss by targeting specific genes. Current treatments include Minoxidil and finasteride, but CRISPR could offer a more precise solution, though it is still expensive and in early stages.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
A user is organizing a group buy for various compounds aimed at reversing hair loss and gray hair, and improving brain health and fat loss. The user has developed a treatment plan based on extensive research and is inviting others to participate, with the option to choose only the compounds they need.
A user shared a beard growth protocol involving hydration toner, azelaic acid, tretinoin, moisturizer, 5% topical minoxidil, and SPF 30+ sunscreen. The regimen spans a year to a year and a half, with specific application schedules for different phases.
A user shared a 15-year experience using minoxidil and finasteride for hair loss, stating that despite never missing a dose, their hairline continued to recede slowly. Other users suggested that the hair loss might be exacerbated by the use of steroids and recommended considering other treatments like dutasteride and RU58841.